Wang, Tianyou
Zhu, Xiaofan
Chen, Yumei
Shen, Shuhong
Tang, Yongmin
Zhang, Jingying
He, Yingyi
Zhang, Hui
Gao, Ju
Fang, Jianpei
Liu, Rong
Wu, Xiaoyan
Sun, Jinchuan
Zhang, Minlu
Funding for this research was provided by:
Sanofi
Article History
Accepted: 29 March 2023
First Online: 10 May 2023
Declarations
:
: This phase IV trial was sponsored by Sanofi.
: Jinchuan Sun and Minlu Zhang are Sanofi employees and may hold shares and/or stock options in the company. The other authors declare no conflicts of interest.
: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
: The study protocol and its subsequent revisions were approved by the independent ethics committees (IECs) and/or institutional review boards (IRBs) (IEC-C-007-A01-V.05), while conforming to the standards of the Declaration of Helsinki and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines for Good Clinical Practice (GCP), all applicable laws, rules, and regulations.
: All patients provided written informed consent before study entry.
: Not applicable.
: Not applicable.
: All authors provided substantial contributions to the interpretation of data for the work and read and approved the final version of the manuscript to be published.